Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly To Start Phase III Trials in Diabetic Peripheral Neuropathy For LY-333531

Executive Summary

Lilly is expanding its Phase III program for the protein kinase C-beta inhibitor LY-333531 to include diabetic peripheral neuropathy

You may also be interested in...



Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market

Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients

Pfizer Adds Muscle To Geodon; IM Could Agitate Schizophrenia Market

Pfizer's intramuscular formulation of Geodon (ziprasidone) is indicated for "rapid control of agitation" in schizophrenic patients

Lilly GMP “Culture Change” Will Address Compliance Issues, Firm Tells FDA

Lilly is seeking to "affect cultural change" in its approach to GMP compliance, the company assured FDA in a response to the most recent FDA-483 manufacturing report for Forteo and Zyprexa IM

Related Content

UsernamePublicRestriction

Register

PS040016

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel